Pharmacyclics seeks additional indication for Imbruvica in USA

8 April 2014
2019_biotech_test_vial_discovery_big

USA-based Pharmacyclics (Nasdaq: PCYC) has submitted a supplemental New Drug Application (sNDA) to the US Food and Drug Administration to gain a wider indication for its mantle cell lymphoma (MCL) treatment Imbruvica (ibrutinib).

The filing is based on data from the randomized, multi-center, open-label Phase III RESONATE study, PCYC-1112, a head-to-head comparison of single agent Imbruvica) versus ofatumumab in 391 patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who had received at least one prior therapy.

Imbruvica is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a unit of US health care giant Johnson & Johnson (NYSE: JNJ). The deal with Janssen involved $150 million upfront and further potential payments of $825 million to Pharmacyclics.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology